| Summary: | The treatment of skull base paragangliomas has moved towards the use of cranial nerve preservation strategies, using radiation therapy and subtotal resection in instances when aiming for gross total resection would be expected to cause increased morbidity compared to the natural history of the tumor itself. The goal of this study was to analyze the role of surgery in patients with skull base paragangliomas treated with CyberKnife stereotactic radiosurgery (SRS) for definitive tumor control. A retrospective review identified 22 patients (median age 65.5 years, 50% female) treated with SRS from 2010–2022. Fourteen patients (63.6%) underwent microsurgical resection. Gross total resection was performed in four patients for tympanic paraganglioma (<i>n</i> = 2), contralateral paraganglioma (<i>n</i> = 1), and intracranial tumor with multiple cranial neuropathies (<i>n</i> = 1). Partial/subtotal resection was performed for the treatment of pulsatile tinnitus and conductive hearing loss (<i>n</i> = 6), chronic otitis and otorrhea (<i>n</i> = 2), intracranial extension (<i>n</i> = 1), or episodic vertigo due to perilymphatic fistula (<i>n</i> = 1). Eighteen patients had clinical and imaging follow-up for a mean (SD) of 4.5 (3.4) years after SRS, with all patients having clinical and radiological tumor control and no mortalities. Surgery remains an important component in the multidisciplinary treatment of skull base paraganglioma when considering other outcomes besides local tumor control.
|
|---|